Cybin(NASDAQ) HELP

Market Cap$780.38M

Since IPO (2020)-52%

5 Year-83%

1 Year+82%

1 Month+61%

$12.63

+1.28%

+0.16Today

After hours$12.72+$0.09 (+0.71%)

Cybin last closing stock price
Metric	Price	Date
Last close	USD 12.59	2026-08-21

Cybin stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+5%	USD 11.99	2026-08-14
1 month	+61%	USD 7.82	2026-07-22
3 month	+169.02%	USD 4.68	2026-05-22
Year to date	+53.91%	USD 8.18	2025-12-31
1 year	+81.94%	USD 6.92	2025-08-21
3 year	+6.91%	USD 11.78	2023-08-22
5 year	-82.56%	USD 72.20	2021-08-20
Since inception	-52.25%	USD 26.36	2020-11-11

Cybin Financials at a Glance

Market Cap

$780.38M

Revenue (TTM)

$0.00

Net Income (TTM)

-$183.27M

EPS (TTM)

-$4.25

P/E Ratio

-2.97

Dividend

$0.00

Beta (Volatility)

1.02 (Average)

Dividend

$0.00

Beta (Volatility)

1.02 (Average)

Price

$12.63

Volume

2,165,244.335

Open

$12.58

Price

$12.63

Volume

2,165,244.335

Open

$12.58

Previous Close

$12.59

Daily Range

$12.47 - $12.95

52-Week Range

$3.76 - $12.95

Estimated Earnings Date

Nov 12, 2026

Dividend

$0.00

Beta (Volatility)

1.02 (Average)

Price

$12.63

Volume

2,165,244.335

Open

$12.58

Previous Close

$12.59

Daily Range

$12.47 - $12.95

52-Week Range

$3.76 - $12.95

Estimated Earnings Date

Nov 12, 2026

HELP News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cybin

Cybin Inc. is a biopharmaceutical company focused on developing innovative therapeutic agents derived from psychedelic compounds. The company is currently in its clinical development phase, with a research pipeline that includes treatments for major depressive disorder and generalized anxiety disorder.

Products and Services

CYB003: A deuterated psilocybin analog for major depressive disorder
CYB004: A deuterated DMT compound targeting generalized anxiety disorder
Research and development of novel psychedelic-based therapies

Growth Outlook

Strong market potential in the mental health treatment sector
Increasing acceptance of psychedelic therapies in clinical settings
Expansion of research collaborations and partnerships

Financial Highlights

Recent quarterly net income of -$46.6 million
Cash and cash equivalents of $166.2 million as of June 30, 2026
Current ratio of 10.97 indicates strong liquidity position

Cybin Inc. operates in a rapidly evolving industry, with a focus on addressing significant mental health challenges through innovative therapies. The company's pipeline products, CYB003 and CYB004, are positioned to meet the growing demand for effective treatments in the mental health space. With increasing acceptance of psychedelic therapies, Cybin is well-placed to capitalize on this trend. Financially, the company maintains a robust liquidity position, supported by substantial cash reserves, which can facilitate ongoing research and development efforts. The current ratio reflects a strong ability to meet short-term obligations, providing a solid foundation for future growth.

AI Generated • Aug 18, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

100

CEO

Eric So

Website

www.cybin.com

Headquarters

Toronto, ON M5X 1C9, CA

HELP Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-74.47%

Return on Capital

-61.00%

Return on Assets

-67.58%

Earnings Yield

-33.67%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$780.38M

Shares Outstanding

61.98M

Volume

2.17M

Avg. Volume

1.50M

Financials (TTM)

Gross Profit

-$30.21K

Operating Income

-$177.17M

EBITDA

-$177.05M

Operating Cash Flow

-$152.97M

Capital Expenditure

-$1.62M

Free Cash Flow

-$154.59M

Cash & ST Invst.

$166.17M

Total Debt

$0.00

Cybin Performance Analysis

Cybin annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2023	2023-03-31	USD 0	N/A
2024	2024-03-31	USD 0	N/A
2025	2025-03-31	USD 0	N/A
2026	2026-03-31	USD 0	N/A

Cybin sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-09-30	N/A
Q3	2025-12-31	N/A
Q4	2026-03-31	N/A
Q1	2026-06-30	N/A

Cybin annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2023	2023-03-31	USD -7.36	-40.0%
2024	2024-03-31	USD -2.89	-60.7%
2025	2025-03-31	USD -4.02	39.0%
2026	2026-03-31	USD -4.25	5.7%

Cybin sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-09-30	-76.4%
Q3	2025-12-31	9.3%
Q4	2026-03-31	47.7%
Q1	2026-06-30	3.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2027YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$30.21K

N/A

Gross Margin

0.00%

N/A

Market Cap

$780.38M

N/A

Market Cap/Employee

$7.80M

N/A

Employees

100

N/A

Net Income

-$46.60M

-89.4%

EBITDA

-$47.81M

-94.5%

Quarterly Fundamentals

Name

Q1 2027YOY CHG

Total Cash

$166.17M

+90.7%

Total Debt

$0.00

-100.0%

Accounts Receivable

$5.03M

+67.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$0.00

N/A

Return on Assets

-67.58%

N/A

Return on Invested Capital

-70.77%

N/A

Free Cash Flow

-$36.44M

-66.7%

Operating Cash Flow

-$36.13M

-66.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,670.48+0.00%

^DJIDJI

^DJIDJI$53,232.98+0.01%

^IXICNASDAQ

^IXICNASDAQ$26,143.12+0.00%

BTCBitcoin

BTCBitcoin$77,344.00+0.06%

SPCXSPCX

SPCXSPCX$135.48+0.01%

AAPLAAPL

AAPLAAPL$308.91-0.01%

AMZNAMZN

AMZNAMZN$258.38-0.01%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.77+0.10%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$43.68+0.06%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.41+0.06%

MARAMara Holdings

MARAMara Holdings$11.26+0.01%

NVDANvidia

NVDANvidia$214.72-0.01%

INTCIntel

INTCIntel$90.07-0.02%

MRNAModerna

MRNAModerna$145.13+0.09%

Questions About HELP

What is the current price of Cybin?

Cybin is trading at $12.59 per share.

What is the 52-week range for Cybin?

Over the past 52 weeks, Cybin has traded between $3.76 and $12.95.

How much debt does Cybin have?

As of the most recent reporting period, Cybin reported total debt of $0.00.

How much cash does Cybin have on hand?

Cybin reported $166.37M in cash and cash equivalents in its most recent financial results.

What is Cybin’s dividend yield?

Cybin does not currently have a dividend yield.

Cybin(NASDAQ) HELP

Cybin Financials at a Glance

HELP News

5 Best Psychedelic Stocks for 2026 and How to Invest

These 4 Psychedelic Biotech Stocks Are Leading the Pack

Buying Cybin Stock Right Now Could Be a Brilliant Move

Missed the Initial Cannabis Boom? Check Out Hot Psychedelic Stock Cybin

3 Reasons to Buy Cybin Stock, and 1 Reason to Sell

Could Cybin Be a Millionaire-Maker Stock?

Forget Sundial Growers: Put This Psychedelic Stock on Your Radar

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Cybin

HELP Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Cybin Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About HELP

What is the current price of Cybin?

What is the 52-week range for Cybin?

How much debt does Cybin have?

How much cash does Cybin have on hand?

What is Cybin’s dividend yield?

Premium Investing Services